Read the full stored bill text
Wisconsin Legislature: SB1149: Bill Text
Skip navigation
Home
Documents
Senate
Assembly
Committees
Service Agencies
Docs
Options
Help
2025 Biennium
Statutes
Admin. Rules
Indices
Miscellaneous
Archives
Home
Bill, Rule, and Appointment Histories
Senators
Representatives
Committees
Text of Introduced Proposals
Amendment Text
Acts
Veto Messages
Enrolled Bills
Votes
Assembly and Senate Floor Calendars
Schedule of Committee Activities
Assembly and Senate Journals
Committee Records (ROCPs)
Legislative Rules
All Session-Related Documents
Subject Index to Acts
Subject Index to Legislation
Subject Index to Journals
Author Index to Legislation
Subject Index to Clearinghouse Rules
Miscellaneous Budget Documents
Executive Orders
Rulings of the Chair
Wisconsin Supreme Court Rules
Opinions of the Attorney General
Town Law Forms
Law
Districts
Session
Drafting Files
Feeds
Preferences
Show tree
Hide tree
Feedback
Help
Home
Senate Home
Senators
Committees
Session
Chief Clerk
Sergeant at Arms
Civics Education
Human Resources
Assembly Home
Representatives
Committees
Session
Chief Clerk
Sergeant at Arms
Human Resources
Schedule
Joint
Senate
Assembly
Study
Legislative Audit Bureau
Legislative Council
Legislative Fiscal Bureau
Legislative Human Resources Office
Legislative Reference Bureau
Legislative Technology Services Bureau
Menu
»
2025
»
Related Documents
»
Proposal Text
»
SB1149: Bill Text
Up
Up
2025 - 2026 LEGISLATURE
LRB-6544/1
SWB:cjs
2025 SENATE BILL 1149
March 19, 2026 - Introduced by Senators
Pfaff
,
Carpenter
,
Dassler-Alfheim
,
Hesselbein
,
Larson
,
Ratcliff
,
Roys
,
Smith
and
Spreitzer
, cosponsored by Representatives
Roe
,
Subeck
,
Bare
,
Brown
,
Clancy
,
DeSanto
,
Emerson
,
Goodwin
,
Hong
,
Joers
,
Kirsch
,
Miresse
,
Moore Omokunde
,
Sinicki
,
Snodgrass
,
Tenorio
,
Udell
,
Vining
and
Anderson
. Referred to Committee on Health.
SB1149,1,3
1
An Act
to create
20.435 (1) (fp) and 146.901 of the statutes;
relating to:
2
prescription drug cost reporting by manufacturers, making an appropriation,
3
and providing a penalty.
Analysis by the Legislative Reference Bureau
This bill requires certain cost reporting by manufacturers of brand-name and generic drugs. The bill requires a manufacturer to notify the Department of Health Services and the Office of the Commissioner of Insurance if it is 1) increasing the wholesale acquisition cost of a brand-name drug on the market in Wisconsin by more than 25 percent over a 24-month period; 2) intending to introduce in Wisconsin a brand-name drug that has an annual wholesale acquisition cost of $30,000 or more; 3) increasing the wholesale acquisition cost of a generic drug on the market in Wisconsin by more than 25 percent or by more than $300 during any 12-month period; or 4) intending to introduce in Wisconsin a generic drug that has an annual wholesale acquisition cost of $3,000 or more. The manufacturer must provide the notice at least 30 days before the planned date of the increase or introduction and must provide a justification including a description described in the bill. A manufacturer is also required to annually report to DHS and OCI the value of price concessions provided to each pharmacy benefit manager for each drug sold in Wisconsin for which a notice was required. The bill also requires each manufacturer of a brand-name or generic drug sold in Wisconsin to submit to DHS and OCI a report containing a description of each manufacturer-sponsored assistance program in effect during the previous year that includes the criteria for participation, the program terms, and the number of prescriptions and the total market value of assistance provided to residents of Wisconsin under the program. The manufacturer must certify the information provided in a notice or report required under the bill under penalty of perjury, and failure to provide the notice or report is subject to a forfeiture determined by DHS but not to exceed $10,000 per day past due.
The bill requires DHS to publish the pricing justification information reported by manufacturers on its website. DHS must also analyze the information and publish a report on its website describing trends in drug pricing.
The bill provides an additional appropriation to DHS for the purpose of administering prescription drug cost reporting by manufacturers and also authorizes 2.0 additional positions for DHS for that purpose.
For further information see the state fiscal estimate, which will be printed as an appendix to this bill.
The people of the state of Wisconsin, represented in senate and assembly, do enact as follows:
SB1149,1
1
Section
1
.
20.005 (3) (schedule) of the statutes: at the appropriate place,
2
insert the following amounts for the purposes indicated:
-
See PDF for table
SB1149,2
9
Section
2
.
20.435 (1) (fp) of the statutes is created to read:
SB1149,2,12
10
20.435
(1)
(fp)
Prescription drug cost reporting by manufacturers.
Biennially,
11
the amounts in the schedule to administer prescription drug cost reporting under s.
12
146.901.
SB1149,3
1
Section
3
.
146.901 of the statutes is created to read:
SB1149,3,3
2
146.901
Prescription drug cost reporting by manufacturers.
(1)
3
Definitions.
In this section:
SB1149,3,5
4
(a) “Brand-name drug” means a prescription drug approved under
21 USC
5
355
(b) or
42 USC 262
.
SB1149,3,6
6
(b) “Generic drug” means a prescription drug approved under
21 USC 355
(j).
SB1149,3,9
7
(c) “Manufacturer” has the meaning given in s. 450.01 (12). “Manufacturer”
8
does not include an entity that is engaged only in the dispensing, as defined in s.
9
450.01 (7), of a brand-name drug or a generic drug.
SB1149,3,13
10
(d) “Manufacturer-sponsored assistance program” means a program offered
11
by a manufacturer or an intermediary under contract with a manufacturer through
12
which a brand-name drug or a generic drug is provided to a patient at no charge or
13
at a discount.
SB1149,3,14
14
(e) “Office” means the office of the commissioner of insurance.
SB1149,3,15
15
(f) “Pharmacy benefit manager” has the meaning given in s. 632.865 (1) (c).
SB1149,3,19
16
(g) “Wholesale acquisition cost” means the most recently reported
17
manufacturer list or catalog price for a brand-name drug or a generic drug available
18
to wholesalers or direct purchasers in the United States, before application of
19
discounts, rebates, or reductions in price.
SB1149,4,2
20
(2)
Price increase or introduction notice; justification report.
(a) A
21
manufacturer shall notify the department and the office if it is increasing the
22
wholesale acquisition cost of a brand-name drug on the market in this state by more
23
than 25 percent over a 24-month period or if it intends to introduce to market in
1
this state a brand-name drug that has an annual wholesale acquisition cost of
2
$30,000 or more.
SB1149,4,7
3
(b) A manufacturer shall notify the department and the office if it is
4
increasing the wholesale acquisition cost of a generic drug on the market in this
5
state by more than 25 percent or by more than $300 during any 12-month period or
6
if it intends to introduce to market in this state a generic drug that has an annual
7
wholesale acquisition cost of $3,000 or more.
SB1149,4,12
8
(c) The manufacturer shall provide the notice under par. (a) or (b) in writing
9
at least 30 days before the planned effective date of the cost increase or drug
10
introduction and shall provide a justification that includes all documents and
11
research related to the manufacturer’s selection of the price increase or
12
introduction price and includes a description of all of the following:
SB1149,4,13
13
1. The estimated cost-effectiveness of the drug.
SB1149,4,15
14
2. The price and effectiveness of similar drugs available in this state and the
15
anticipated sales performance of the drug as compared to similar drugs.
SB1149,4,18
16
3. The impact of negotiated or mandated discounts to pharmacy benefit
17
managers, insurers, and other payers of health care costs on the pricing
18
determination for the drug.
SB1149,4,23
19
(d) By March 1 annually, each manufacturer shall report to the department
20
and the office the value of price concessions, expressed as a percentage of the
21
wholesale acquisition cost, provided to each pharmacy benefit manager for each
22
drug sold by the manufacturer in this state for which a notice is required under par.
23
(a) or (b) in the previous calendar year.
SB1149,5,5
1
(3)
Manufacturer-sponsored assistance programs.
By March 1 annually,
2
each manufacturer of a brand-name drug or generic drug sold in this state shall
3
submit to the department and the office a report containing a description of each
4
manufacturer-sponsored assistance program in effect during the previous calendar
5
year that includes all of the following:
SB1149,5,7
6
(a) The criteria for participation in the manufacturer-sponsored assistance
7
program and the manufacturer-sponsored assistance program terms.
SB1149,5,9
8
(b) The number of prescriptions provided to residents of this state under the
9
manufacturer-sponsored assistance program.
SB1149,5,11
10
(c) The total market value of assistance provided to residents of this state
11
under the manufacturer-sponsored assistance program.
SB1149,5,16
12
(4)
Penalty.
The manufacturer shall certify the information reported under
13
sub. (2) or (3) as accurate under penalty of perjury. A manufacturer that fails to
14
provide the notice or report under sub. (2) or (3) is subject to a forfeiture as
15
determined by the department but not to exceed $10,000 for each day the notice or
16
report is past due.
SB1149,5,18
17
(5)
Posting of report; hearing.
(a) The department shall publish on its
18
website the justification documentation provided under sub. (2) (c).
SB1149,5,22
19
(b) The department shall analyze the information submitted under subs. (2)
20
and (3) and publish a report on its website describing trends in drug pricing. The
21
department shall conduct at least one public hearing annually on the findings of
22
the report.
SB1149,4
23
Section
4
. Nonstatutory provisions.
SB1149,6,4
1
(
1
)
Prescription drug cost reporting by manufacturers.
The authorized
2
FTE positions for the department of health services are increased by 2.0 GPR
3
positions, to be funded from the appropriation under s. 20.435 (1) (fp), for the
4
purpose of administering prescription drug cost reporting under s. 146.901.
SB1149,6,5
5
(end)
Down
Down
/2025/related/proposals/sb1149
true
proposaltext
/2025/related/proposals/sb1149
proposaltext/2025/REG/SB1149
proposaltext/2025/REG/SB1149
section
true
Menu
»
2025
»
Related Documents
»
Proposal Text
»
SB1149: Bill Text
×
Details for
PDF view
Link
(Permanent link)
Bookmark this location
View toggle
Go to top of document
Search in this chapter
Search in this section
Search in this agency
Search in this chapter group
Search in this chapter
Search in this section
Cross references for section
Acts affecting this section
References to this
1970 Statutes Annotations
Appellate Court Citations
Administrative Code Index
Reference lines
Clear highlighting